IL6 and Miyoshi myopathy: Hence, depending onthe type of malignancies and its role in cancer progression,EZH2 can be considered as onco/tumor suppressor gene.The mechanisms of these misregulations are different.For example in MM, interleukin-6 (IL-6) and c-Mycactivation can mediated EZH2 up-regulation (11, 12).Different subsets of genes, having important roles in MMpathogenesis, are affected by EZH2 silencing impact.